Trials / Unknown
UnknownNCT02506452
Postmarket Study to Evaluate Biovance® in Diabetic Foot Ulcers
Evaluation of Biovance, a Dehydrated Decellularized Human Amniotic Membrane Allograft, in Diabetic Foot Ulcers
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Alliqua BioMedical, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the wound closure outcomes of subjects receiving diabetic foot ulcer treatment with and without the use of Biovance®.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Biovance® | Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading |
| OTHER | Standard of Care, Diabetic Foot Ulcers | Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2017-06-01
- Completion
- 2017-12-01
- First posted
- 2015-07-23
- Last updated
- 2017-05-17
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02506452. Inclusion in this directory is not an endorsement.